Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i> Mutant Pancreatic CancerCraig M. Goodwin, Channing J. Der, Runying Yang et al.|Cancer Research|2022Cited by 160
PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicineElisa Baldelli, Mariaelena Pierobon|Journal for ImmunoTherapy of Cancer|2021Cited by 14
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.Mareen Lüthen, Sehrish Javaid, Jennifer E. Klomp et al.|UNC Libraries|2024Cited by 12
RHOA<sup>L57V</sup>drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signalingAntje Schaefer, Channing J. Der, Richard G. Hodge et al.|Science Signaling|2023Cited by 9
Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic CancerCraig M. Goodwin, Channing J. Der, Andrew M. Waters et al.|Unknown|2023Cited by 0